TriLink Biotechnologies Announces Supplier Agreement with Applied Biosystems
News Nov 08, 2007
TriLink Biotechnologies announced that it has signed a service agreement with Applied Biosystems to supply reagents for Applied Biosystems' recently launched next-generation genetic analysis platform, the SOLiD™ System.
As part of the agreement, TriLink is providing Applied Biosystems with custom dye-labeled oligonucleotides, or chemically synthesized nucleotides, which are used as part of the DNA sequencing process.
"Working with best-in-class suppliers like TriLink has enabled us to develop the most robust, accurate, and highest-throughput genetic analysis platform available to help our customers take advantage of the emerging applications for next-generation DNA sequencing," said Kim Caple, vice president and general manager for Applied Biosystems' next-generation sequencing business.
"We are proud that Applied Biosystems has chosen TriLink to be the supplier of the oligonucleotides used in the SOLiD™ system," said TriLink CEO, Dr. Richard Hogrefe.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.